Here's a bit of good news for a biotech stock that's having a rough day. FibroBiologics Inc. (FBLG) announced Tuesday that it has finished making the first batch of its experimental drug, CYWC628. This isn't just any batch—it's the one that's supposed to be used in the first-ever human tests of the therapy, which is designed to treat diabetic foot ulcers.
The manufacturing was done under the FDA's strict Good Manufacturing Practices (CGMP). The company says the batch will be released for use once it passes all the required safety and quality checks. So, think of it as a major box checked on the long, winding road to getting a new drug approved.
Targeting a Painful Problem
So, what's CYWC628 for? It's a fibroblast-based therapy aimed at diabetic foot ulcers. If you're not familiar, a diabetic foot ulcer is essentially an open sore, usually on the bottom of the foot. It's a nasty complication of diabetes, caused by nerve damage and poor blood flow, and it affects up to 15% of people with the disease. The real kicker is that there aren't many great long-term treatment options out there for the millions of patients worldwide who suffer from them.
"CYWC628 is not only the first fibroblast-based spheroid therapeutic candidate, its manufacture also represents the first large-scale CGMP manufacturing of a spheroid product for therapeutic use," said Pete O'Heeron, Founder & CEO of FibroBiologics. In biotech speak, that's a pretty big deal—it's a novel approach being produced at scale for the first time.
Clinical Plans and Corporate Moves
What's next? Human trials. O'Heeron added, "These achievements by our scientific team allow us to move forward with our planned Phase 1/2 clinical trial utilizing CYWC628 in DFU patients in the first half of 2026."
The pipeline progress announcement comes with some other corporate news in the background. Last week, the company approved a 1-for-20 reverse stock split, which went into effect Tuesday. Reverse splits are often a move to boost a stock's per-share price, sometimes to meet exchange listing requirements.
And FibroBiologics isn't putting all its eggs in one basket. Back in December 2025, the company filed a Phase 1/2 Investigational New Drug (IND) application with the FDA for another therapy called CYPS317. That one is an investigational treatment for moderate to severe psoriasis, also based on its fibroblast spheroid technology.
As for the stock? It was having a tough Tuesday. Shares of FibroBiologics were down 36.4% at $1.445 at the time of publication, according to market data. It's a reminder that in biotech, promising science and a plunging stock price can, and often do, happen on the same day.
